New Release: Alpha testing version has been released.

Nicotine

N07B - Drugs used in addictive disorders ATC N07B01 Small molecule approved 1984 Oral Topical Natural product

JFDA label: Nicorette Chew Gum

Mechanism of Action

Agonist of Neuronal acetylcholine receptor; alpha4/beta2 — Neuronal acetylcholine receptor; alpha4/beta2 agonist

TargetActionGene / class
Neuronal acetylcholine receptor; alpha4/beta2 efficacy AGONIST

Indications

Approved

  • Smoking cessation

Contraindications

Source: Lexicomp

  • Hypersensitivity to nicotine or any component of the formulation. OTC labeling: Nicorette lozenge: When used for self-medication, do not use if you are allergic to soya Absolute

Adverse Reactions

Very Common >10%Common 1–10%Uncommon 0.1–1% Rare 0.01–0.1%Very Rare <0.01%Not Known

Nervous system disorders (9)

Very Common Headache

Common Withdrawal syndrome

Not Known Depression · dizziness · insomnia · lack of concentration · nervousness · pain · paresthesia

Renal and urinary disorders (1)

Common Dysmenorrhea

Immune system disorders (1)

Not Known Hypersensitivity reaction

Gastrointestinal disorders (16)

Very Common dyspepsia · Inhaler: Mouth irritation

Common diarrhea · dysgeusia · Flatulence · gingival disease · hiccups · nausea · tooth enamel damage (abrasions)

Not Known Aphthous stomatitis · constipation · gingival hemorrhage · glossitis · sialorrhea · stomatitis · xerostomia

Skin and subcutaneous tissue disorders (4)

Common Acne vulgaris · burning sensation of the nose (nasal spray)

Not Known Diaphoresis · Skin rash

Musculoskeletal and connective tissue disorders (5)

Common arthralgia · Back pain · jaw pain · neck pain

Not Known myalgia

General disorders and administration site conditions (3)

Not Known Application site reaction · localized edema · localized erythema

Respiratory, thoracic and mediastinal disorders (4)

Very Common cough · Inhaler: Throat irritation · rhinitis

Common Sinusitis

Dosing

Source: Lexicomp

Smoking cessation (patients should completely stop smoking upon initiation of therapy): Gum: Chew 1 piece of gum when urge to smoke occurs. If strong or frequent cravings are present after 1 piece of gum, may use a second piece within the hour (do not continuously use one piece after the other). Patients who smoke their first cigarette within 30 minutes of waking should use the 4 mg strength; otherwise the 2 mg strength is recommended. Use according to the following 12-week dosing schedule: Weeks 1 to 6: Chew 1 piece of gum every 1 to 2 hours (maximum: 24 pieces/day); to increase chances of quitting, chew at least 9 pieces/day during the first 6 weeks Weeks 7 to 9: Chew 1 piece of gum every 2 to 4 hours (maximum: 24 pieces/day) Weeks 10 to 12: Chew 1 piece of gum every 4 to 8 hours (maximum: 24 pieces/day) Inhalation: Oral: Initial treatment: 6 to 16 cartridges/day (at least 6 cartridges/day for the first 3 to 6 weeks) for up to 12 weeks; maximum: 16 cartridges/day. Note: Best effect achieved with frequent continuous puffing (20 minutes). Use beyond 6 months is not recommended (has not been studied). If patient is unable to stop smoking by the fourth week of therapy, consider discontinuation. Discontinuation of therapy: After initial treatment, gradually reduce daily dose over 6 to 12 weeks. Some patients may not require gradual reduction of dosage and may stop treatment abruptly. Lozenge: Oral: 1 lozenge when urge to smoke occurs; do not use more than 1 lozenge at a time. Patients who smoke their first cigarette within 30 minutes of waking should use the 4 mg strength; otherwise the 2 mg strength is recommended. Use according to the following 12-week dosing schedule: Weeks 1 to 6: 1 lozenge every 1 to 2 hours (maximum: 5 lozenges every 6 hours; 20 lozenges/day); to increase chances of quitting, use at least 9 lozenges/day during the first 6 weeks Weeks 7 to 9: 1 lozenge every 2 to 4 hours (maximum: 5 lozenges every 6 hours; 20 lozenges/day) Weeks 10 to 12: 1 lozenge every 4 to 8 hours (maximum: 5 lozenges every 6 hours; 20 lozenges/day) Nasal: Spray: Initial: 1 to 2 doses/hour (each dose [2 sprays, one in each nostril] contains 1 mg of nicotine); adjust dose as needed based on patient response; do not exceed more than 5 doses (10 sprays) per hour [maximum: 40 mg/day (80 sprays)] or 3 months of treatment. Note: For best results, use at least the recommended minimum of 8 doses per day (less is unlikely to be effective). Use beyond 6 months is not recommended (has not been studied). If patient is unable to stop smoking by the fourth week of therapy, consider discontinuation. Discontinuation of therapy: Discontinue over 4 to 6 weeks. Some patients may not require gradual reduction of dosage and may stop treatment abruptly. Transdermal patch: Topical: Note: Adjustment may be required during initial treatment (move to higher dose if experiencing withdrawal symptoms; lower dose if side effects are experienced). Patients smoking >10 cigarettes/day: Begi
Refer to adult dosing.
There are no dosage adjustments provided in the manufacturer's labeling (has not been studied). Only severe renal impairment should affect clearance of nicotine or its metabolites from circulation.
There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); because total system clearance of nicotine is dependent on hepatic blood flow, anticipate reduced clearance.

Warnings & Precautions

Source: Lexicomp

Cardiovascular disease

Nicotine can increase heart rate and blood pressure. The risk versus the benefits should be weighed in patients with cardiovascular or peripheral vascular diseases, specifically patients with a history of myocardial infarction and/or angina pectoris, serious cardiac arrhythmias, or vasospastic diseases (Buerger disease, Prinzmetal variant angina, Raynaud phenomena); use caution in patients with angina, hypertension, or recent MI. Discontinue use if irregular heartbeat or palpitations occur. Use caution in patients with accelerated hypertension due to the risk of malignant hypertension. Generally, avoid use during the immediate postmyocardial infarction period, in patients with serious arrhythmias, or with severe or worsening angina.

Diabetes

Use with caution in patients with insulin-dependent diabetes.

Gastrointestinal disease

Use with caution in patients with active peptic ulcer disease; healing may be delayed.

Hepatic impairment

Use with caution in patients with severe hepatic impairment; effects on metabolism unknown.

Hyperthyroidism

Use with caution in patients with hyperthyroidism.

Pheochromocytoma

Use with caution in patients with pheochromocytoma.

Renal impairment

Use with caution in patients with severe renal impairment; effects on elimination unknown. Dosage form specific issues:

Chewing gum

OTC labeling: When used for self-medication, consult a health care provider before use in patients on a sodium-restricted diet and in patients with a history of seizures. Discontinue use and consult a health care provider if mouth, teeth, or jaw problems occur.

Inhaler

Use with caution in patients with bronchospastic disease (eg, asthma, chronic pulmonary disease); may cause bronchospasm due to potential airway irritation; other forms of nicotine replacement may be preferred in patients with severe bronchospastic airway disease. Sustained use (beyond 6 months) by patients who quit smoking is not recommended.

Lozenge

OTC labeling: When used for self-medication, consult a health care provider before use in patients on a sodium-restricted diet and in patients with a history of seizures. Discontinue use and consult a health care provider if mouth problems, persistent indigestion, or severe sore throat occurs.

Nasal spray

Use of nasal product is not recommended with chronic nasal disorders (eg, allergy, rhinitis, nasal polyps, and sinusitis). Exacerbations of bronchospasm have been reported in patients with preexisting asthma; use in patients with severe reactive airway disease is not recommended. Nasal mucosa irritation may occur. Sustained use (beyond 6 months) by patients who quit smoking is not recommended.

Transdermal patch

May contain conducting metal (eg, aluminum); remove patch prior to MRI. OTC labeling: When used for self-medication, consult a health care provider before use in patients who have an allergy to adhesive tape or who have skin problems. Discontinue use and contact a health care provider if skin redness caused by the patch does not resolve after 4 days or if inflammation or rash occurs. If vivid dreams or other sleep disturbances occur, remove the patch at bedtime and apply another patch in the morning. Other warnings/precautions:

Appropriate use

Urge patients to stop smoking completely when initiating therapy.

OTC labeling

When used for self-medication, discontinue use and contact a health care provider if symptoms of nicotine overdose (eg, nausea, vomiting, dizziness, diarrhea, weakness, rapid heartbeat) or an allergic reaction (eg, difficulty breathing, rash) occurs.

Pregnancy & Lactation

Pregnancy

Nicotine crosses the placenta (HHS 2014). Maternal smoking is associated with birth defects (HHS 2014; Hachshaw 2011); the incidence of birth defects following nicotine replacement therapy may be similar (limited data) (Dhalwani 2015). Nicotine exposure via cigarette smoke may cause increased ectopic pregnancy, low birth weight, increased risk of spontaneous abortion, increased perinatal mortality; increased aortic blood flow, increased heart rate, decreased uterine blood flow, and decreased breathing have been reported in the fetus. Smoking during pregnancy is associated with sudden infant death syndrome (SIDS), an increased risk of asthma, infantile colic, and childhood obesity (ACOG 2010; HHS 2014). Women who are pregnant should be encouraged not to smoke. The use of nicotine replacement products to aid in smoking cessation has not been adequately studied in pregnant women (amount of nicotine exposure is varied). Nonpharmacologic treatments are recommended. If the benefits of nicoti

Lactation

Nicotine from cigarette smoke is present in breast milk and can be absorbed orally by the infant; hepatic clearance is likely lowest at birth. The amount of nicotine in breast milk from replacement products varies. Nicotine replacement therapy is considered to be compatible with breastfeeding if the amount of nicotine is less than that received from smoking. Use of short acting products (gum, lozenges) is preferred (Sachs 2013). The manufacturer recommends that caution be exercised when administ

Monitoring

Clinical pearlSigns and symptoms of nicotine toxicity (eg, severe headache, dizziness, mental confusion, disturbed hearing and vision, abdominal pain; rapid, weak and irregular pulse; salivation, nausea, vomiting, diarrhea, cold sweat, weakness)

Chemistry & Properties

2D structure
FormulaC10H14N2
Molecular weight162.24 g/mol
IUPAC name3-[(2S)-1-methylpyrrolidin-2-yl]pyridine
CAS54-11-5
PubChem CID89594
InChIKeySNICXCGAKADSCV-JTQLQIEISA-N
logP1.85 (XLogP 1.2)
Polar surface area16.13 Ų
H-bond acceptors / donors2 / 0
Drug-likeness (QED)0.63
Lipinski violations0
SMILESCN1CCC[C@H]1c1cccnc1

Biology & Pharmacokinetics

Pharmacokinetics

BBB penetrantYes (logBB 0.4)

Enzyme interactions

EnzymeRoleDetail
CYP1A2Substrate
CYP2B6Inhibitor
CYP2B6Substrate
CYP2C19Inhibitor
CYP2C19Substrate
CYP2C8Inhibitor
CYP2C9Substrate
CYP2D6Substrate
CYP3A4Substrate

Receptor binding (top 18)

TargetActionAffinity
Neuronal acetylcholine receptor protein alpha-4 subunit (CHRNA4) Binding pKi 8.8
Cholinergic, Nicotinic Alpha4Beta2 Binding pKi 8.8
nicotinic acetylcholine receptor &alpha;4 subunit (CHRNA4) Agonist pKi 8.7
Cholinergic, Nicotinic Alpha2Beta2 Binding pKi 8.5
Nicotinic Alpha2Beta2 Binding pKi 8.4
Nicotinic Alpha4Beta2 Binding pKi 8.3
Nicotinic Alpha3Beta2 Binding pKi 8.1
Cholinergic, Nicotinic Alpha3Beta2 Binding pKi 8.1
Nicotinic Alpha4Beta4 Binding pKi 7.6
Nicotinic Alpha2Beta4 Binding pKi 7.1
Cholinergic, Nicotinic Alpha3Beta4 Binding pKi 6.7
Nicotinic Alpha7 Binding pKi 6.7
Nicotinic Alpha3Beta4 Binding pKi 6.5
Cholinergic, Nicotinic Alpha4Beta4 Binding pKi 6.4
Cholinergic, Nicotinic Alpha2Beta4 Binding pKi 6.2

Transporters

BCRP (Inhibitor)BCRP (Inhibitor)BSEP (Inhibitor)BSEP (Inhibitor)MATE1 (Inhibitor)MATE2 (Inhibitor)MCT1 (Inhibitor)MRP1 (Inhibitor)MRP2 (Inhibitor)MRP3 (Inhibitor)MRP4 (Inhibitor)OATP1B1 (Inhibitor)OATP1B1 (Inhibitor)OATP1B3 (Inhibitor)OATP1B3 (Inhibitor)OATP2B1 (Inhibitor)OCT1 (Inhibitor)OCT2 (Inhibitor)OCT3 (Inhibitor)OCTN1 (Inhibitor)OCTN2 (Inhibitor)P-gp (Inhibitor)MATE1 (Substrate)MATE2 (Substrate)MDR1 (Substrate)MRP2 (Substrate)P-gp (Substrate)

Drug–drug interactions (9, DDInter)

Interacting drugSeverityManagement
Alpelisib moderate
Bupropion moderate
Ceritinib moderate
Caffeine minor
Cimetidine minor
Famotidine minor
Nizatidine minor
Ranitidine minor
Ranitidine (bismuth citrate) minor

Registered Products (34)

BrandForm / strengthPackAgentCitizen (JOD)
Nicotinell Fruit Gum Tablet 2 ( resinate) mg 12 tab pack varies Nabulsi Drug Store 1.700
Nicotinell Mint Gum Tablet 2 ( resinate) mg 12 tab pack varies Nabulsi Drug Store 1.700
Nicotinell Lozenges Tablet 1 mg 12 tab pack varies Sukhtian Group 2.410
Nicotinell Fruit Gum Tablet 4 (as resinate) mg 12 tab pack varies Nabulsi Drug Store 2.450
Nicotinell Mint Gum Tablet 4 (as resinate) mg 12 tab pack varies Nabulsi Drug Store 2.450
Nicotinell Fruit Gum Tablet 2 ( resinate) mg 24 tab pack varies Sukhtian Group 3.920
Nicotinell Mint Gum Tablet 2 ( resinate) mg 24 tab pack varies Sukhtian Group 3.920
Nicorette Chew Gum Chewable Tablet 2 mg 30 tab pack varies Al-Amad Drug Store 4.080
Nicorette Fresh Fruit Lozenge 2 mg 30 Gum Al-Amad Drug Store 4.080
Nicorette Freshmint Lozenge 2 mg 30 Gum Al-Amad Drug Store 4.080
Nicotinell Fruit Gum Tablet 4 (as resinate) mg 24 tab pack varies Nabulsi Drug Store 4.650
Nicotinell Mint Gum Tablet 4 (as resinate) mg 24 tab pack varies Nabulsi Drug Store 4.650
Nicorette Chew Gum Chewable Tablet 4 mg 30 tab pack varies Al-Amad Drug Store 5.860
Nicorette Fresh Fruit Lozenge 4 mg 30 Gum Al-Amad Drug Store 5.870
Nicorette Freshmint Lozenge 4 mg 30 Gum Al-Amad Drug Store 5.870
Niquitin 2 mg Mint Lozenge 2 mg 24 Lozenges pack varies Sukhtian Group 6.800
Niquitin 4mg Mint Lozenge 4 mg 24 (Lozenges) pack varies Sukhtian Group 6.800
Nicotinell Lozenges Tablet 1 mg 36 tab pack varies Sukhtian Group 6.820
Nicotinell Fruit Gum Tablet 2 ( resinate) mg 48 tab pack varies Sukhtian Group 7.690
Nicotinell Mint Gum Tablet 2 ( resinate) mg 48 tab pack varies Sukhtian Group 7.690
Clear Assiquit 10mg/16hr Patches Patch 10 mg/16hr 7 UNITED PHARM.MFG.CO.LTD(UPM)/JORDAN 9.210
Clear Assiquit 15mg/16hr Patches Patch 15 mg/16hr 7 UNITED PHARM.MFG.CO.LTD(UPM)/JORDAN 9.210
Clear Assiquit 5mg/16 hr Patches Patch 5 mg/16hr 7 UNITED PHARM.MFG.CO.LTD(UPM)/JORDAN 9.210
Niquitin 2 mg Mint Lozenge 2 mg 48 Lozenges pack varies Sukhtian Group 10.100
Niquitin 4mg Mint Lozenge 4 mg 48 (Lozenges) pack varies Sukhtian Group 10.100
Nicorette Chew Gum Chewable Tablet 2 mg 105 tab pack varies Al-Amad Drug Store 11.770
Nicorette Invisipatch 10mg/16hours Patch 15.8 mg 7 Al-Amad Drug Store 12.700
Nicorette Invisipatch 15mg/16hours Patch 23.6 mg 7 Al-Amad Drug Store 12.700
Nicorette Invisipatch 25mg/16 hours Patch 39.37 mg 7 Al-Amad Drug Store 12.700
NICOTINELL 10CM PATCHES Patch 17.5 mg/Patch 7 patch Sukhtian Group 13.240
NICOTINELL 20CM PATCHES Patch 35 mg/Patch 7 patch Sukhtian Group 13.240
NICOTINELL 30CM PATCHES Patch 52.5 mg/Patch 7 patch Sukhtian Group 13.240
Nicotinell Lozenges Tablet 1 mg 96 tab pack varies Sukhtian Group 14.260
Nicorette Chew Gum Chewable Tablet 4 mg 105 tab pack varies Al-Amad Drug Store 14.900